This article discusses how Malaysian courts handle derivative actions in family companies. We break down the Sun Pharmaceutical case and Companies Act 2016 requirements.
When a Marriage Breaks Down, the Business Bleeds
It is a quiet kind of devastation when a family company becomes the primary casualty of a divorce. In Kuala Lumpur, a well-established pharmaceutical distributor found itself caught in the crossfire. Foreign partners, spooked by the sudden arrival of lawyers at the company secretary’s office, began terminating decades-old distribution agreements. In the frantic scramble to salvage the business, a new entity was quietly born—set up by trusted senior employees. To the husband, it looked like corporate theft. To the wife, it was a desperate rescue mission.
This is the factual backdrop of Dato’ Dr Lim Boon Ping v. Sun Pharmaceutical Sdn Bhd, a 2020 High Court decision that provides a masterclass on the tensions between matrimonial strife and corporate governance. More importantly, it offers crucial clarity for company directors and shareholders on when a minority can invoke the Companies Act 2016 to sue on behalf of the company.
The Unravelling of a Family Enterprise
Sun Pharmaceutical Sdn Bhd (SPSB) was, by all accounts, a classic Malaysian family enterprise. Wong Fong Leng, the driving force behind the business, held 50% of the shares and served as Managing Director. Her husband, Dato’ Dr Lim Boon Ping—a prominent orthopaedic surgeon—held the other 50% and sat on the board. Their two children were also appointed as directors. For years, the machinery of the business ran smoothly, importing and distributing specialised medical and pharmaceutical products.
The equilibrium shattered in 2018 when the marriage irretrievably broke down and Dr Lim moved out of the matrimonial home. Shortly after, Wong received an alert: her husband had arrived at the company secretary’s office with his lawyers, demanding to inspect the company’s books, management accounts, and banking records.
For Wong, this was not a director exercising his statutory rights; it was a hostile incursion. She immediately informed SPSB’s foreign principals—Pharma Nord ApS and Celeste (S) Pte Ltd (acting for Green Cross Corporation). The principals were deeply concerned. They did not want their products entangled in protracted domestic litigation. Consequently, they terminated their exclusive distribution agreements with SPSB.
Because SPSB lost its exclusive distributor status, it could no longer hold the product registrations and licences. To prevent the total loss of the Malaysian market for these products, the foreign principals required a new local entity to take over the licences. In what Wong described as an exigent circumstance, SPSB’s own employees—Mazuriah Abu Darin (who handled licensing) and Gan Jia Swee (who handled finance)—were asked by the principals to incorporate a new company, Sino Health Sdn Bhd, to hold these licences. Wong, as Managing Director, consented to this arrangement, noting that Sino Health would simply appoint SPSB as its wholesaler.
Dr Lim, however, saw a darker reality. To him, Sino Health was a direct competitor. He alleged that Wong, Mazuriah, and Gan had orchestrated the transfer of valuable pharmaceutical licences out of SPSB—effectively dissipating the company’s assets right under his nose.
The Legal Battle: Clash of Perspectives
With the board deadlocked by the marital dispute, Dr Lim turned to the courts. He filed an Originating Summons under Section 347 of the Companies Act 2016, seeking leave to commence a “derivative action”—a lawsuit brought by a shareholder in the name of the company against those who have allegedly harmed it.
The legal battle that unfolded hinged on two completely divergent narratives.
The Plaintiff’s Case: Protecting the Company from Dissipation
Dr Lim argued that Wong had breached her fiduciary duties under Sections 213(1) and 218 of the Companies Act 2016. He claimed she failed to act in good faith and used her position to benefit Sino Health at the expense of SPSB. Furthermore, he argued that Mazuriah and Gan breached their duties of fidelity as employees. Because the wrongdoers controlled the company, the board would never sue itself. Therefore, he argued, he had no choice but to step in and seek declarations and damages on behalf of SPSB.
The Defendant’s Case: The “Family Company” Defence and Bad Faith
SPSB and Wong mounted a multi-pronged defence.
First, they raised a procedural objection: Dr Lim had not called for a board meeting to discuss the lawsuit before running to court. They argued he had failed to exhaust the company’s internal processes.
Second, they attacked the substance of the claim, arguing that SPSB was a “family company.” Wong asserted she was the true founder and sole beneficial owner, and that Dr Lim was merely a nominee director and shareholder—a relic of the old Companies Act 1965, which did not allow single-shareholder companies. Because Dr Lim was a medical professional bound by the Malaysian Medical Council’s Code of Professional Conduct, he had historically stayed out of the pharmaceutical business to avoid conflicts of interest.
Finally, they attacked Dr Lim’s motives. Wong argued that the derivative action was brought in bad faith for a “collateral purpose.” She pointed out that Dr Lim had simultaneously filed a Cross-Petition in the divorce proceedings demanding that Wong buy out his 50% shares. She alleged he was using the threat of a corporate lawsuit to wreak havoc on SPSB’s operations and pressure her into a favourable divorce settlement.
Key Authorities and Laws Considered by the Court
In determining this application, Judicial Commissioner Liza Chan Sow Keng conducted a meticulous survey of both local and Commonwealth jurisprudence. The following authorities formed the bedrock of the decision:
Statutes & Subsidiary Legislation
- Companies Act 2016, Sections 345, 347, and 348: The statutory regime governing derivative actions in Malaysia. Section 347 allows a complainant to sue on behalf of the company with the Court’s leave. Section 348 sets out the procedural gateways, including a mandatory 30-day written notice and the twin tests for granting leave: “good faith” and “best interests of the company.”
- Companies Act 1965, Sections 181, 181A, and 181B: The predecessor provisions to the current CA 2016. The Court noted that while the substance is similar, the CA 2016 expressly abrogates the common law right to bring derivative actions (s 347(3)).
Case Authorities
- Abdul Rahim Suleiman & Anor v. Faridah Md Lazim & Ors [2016] 6 MLJ 449: A crucial Court of Appeal decision establishing that there is no statutory requirement for a complainant to exhaust a company’s internal processes (like holding board meetings) before applying for leave under the Act.
- Suhaimi bin Ibrahim & Ors v. Hi-Summit Construction Sdn Bhd [2015] 2 MLJ 669: Previously relied upon to suggest internal remedies must be exhausted. The Court in Sun Pharmaceutical distinguished this case, noting it involved specific facts where the Court itself had ordered a board meeting that failed to materialise.
- Celcom (Malaysia) Bhd v. Mohd Shuaib Ishak [2011] 3 MLJ 636: The leading Malaysian authority on the “good faith” test, adopting a two-fold approach: (1) an honest belief in a good cause of action, and (2) the absence of a collateral purpose.
- Swansson v. RA Pratt Properties Pty Ltd [2002] NSWSC 58 (Australia): Heavily relied upon to explain that leave to bring a derivative action must not be given lightly, and to define the interplay between honest belief and collateral purpose.
- Ang Thiam Swee v. Low Hian Chor [2013] 2 SLR 340 (Singapore): Cited for the proposition that questionable motivations only amount to bad faith if they cloud the applicant’s judgment to the point that the company’s interests will not be served. It highlights the distinction between motive (personal animosity) and purpose (serving the company).
- Primex Investments Ltd v. Northwest Sports Enterprise Ltd [1996] 4 WWR 54 (Canada) & Tremblett v. SCB Fisheries Ltd (1993) 116 Nfld & PEIR 139 (Canada): Used to establish that an applicant acting out of self-interest (e.g., to increase share value) is not lacking in good faith, provided that self-interest coincides with the company’s interests. Tremblett also establishes that the burden of proving good faith lies squarely on the applicant.
- Young v. Bristol Aeroplane Co Ltd [1944] KB 718 (UK): The classic rule on precedent, referenced to explain that if there were any conflict between the Suhaimi and Abdul Rahim cases, the latter decision must prevail.
- Yap Yong Huat & Anor v. Yap Yoke Beng [2015] MLJU 1190: Referenced for the Defendant’s argument regarding the unique, non-commercial dynamics of “family companies” and the “iron bowl” concept where shares are gifted rather than earned.
The Court’s Decision: Plain English Explanation
The Court allowed Dr Lim’s appeal, effectively granting him the leave required to commence the derivative action. Judicial Commissioner Liza Chan broke the decision down into four distinct issues.
1. The “Premature” Objection Failed
The Court firmly rejected the argument that Dr Lim needed to hold a board meeting first. Applying a strict reading of Section 348(2) of the CA 2016, the Judge noted that the statute only requires the complainant to give 30 days’ written notice of their intention to apply for leave. The law does not say the complainant must try to resolve the dispute internally first. To read such a requirement into the statute would be to rewrite the law. The Court distinguished the Suhaimi case, confirming that Abdul Rahim Suleiman is the correct prevailing authority in Malaysia: internal processes need not be exhausted.
2. Good Faith and Cause of Action are Interlinked
The Court tackled the complex issue of “good faith” by synthesising a vast array of Commonwealth authorities. The Judge clarified that:
- The burden is on the applicant to positively prove they are acting in good faith; it is not automatically presumed.
- Good faith has two parts: (a) an honest belief that the action has a reasonable prospect of success, and (b) that the action is not an abuse of process for a collateral purpose.
- Crucially, personal animosity or self-interest does not equal bad faith. A shareholder can hate the director personally, and can personally benefit from the lawsuit, but still act in good faith so long as the purpose of the lawsuit is to benefit the company.
3. The Outcome
While the provided judgment extracts extensively map out the legal framework for assessing good faith and “best interests” (noting that bad faith is usually inferred from a lack of an arguable case), the Court ultimately concluded that Dr Lim had crossed the procedural threshold. By allowing the appeal, the Court sanctioned the derivative action to proceed to trial, where the actual evidence of asset dissipation and bad faith would be fully tested.
Significance and Practical Takeaways
The Sun Pharmaceutical decision is a vital read for Malaysian corporate lawyers, business owners, and company directors for several reasons:
1. Clarification on Internal Remedies
For years, there was lingering confusion over whether a shareholder must try to convene a board meeting before seeking court intervention. This case firmly shuts the door on that requirement. If you are a minority shareholder facing a hostile board, you do not need to waste time demanding meetings that will inevitably be blocked or voted down. Your 30-day written notice is your golden ticket to court.
2. The Reality of “Family Company” Defences
Wong’s defence heavily relied on the “family company” trope—arguing that formal corporate rules should bend to accommodate the familial context where one spouse was merely a nominee. The Court’s decision to allow the derivative action signals that Malaysian courts will not easily allow the “family company” label to shield potential breaches of fiduciary duty from scrutiny. The statutory protections under the CA 2016 apply equally to family businesses and public conglomerates.
3. Marital Litigation and Corporate Strategy
This case perfectly illustrates the “scorched earth” tactics often seen in high-net-worth divorces. When a company is a matrimonial asset, shareholders must be acutely aware that their personal disputes can give rise to statutory corporate claims. Conversely, controlling shareholders must be incredibly careful about how they restructure company assets during a divorce. What seems like a pragmatic business rescue (moving licences to a new entity to appease foreign principals) can easily be framed as asset dissipation by an aggrieved spouse.
4. The High Bar for Proving “Bad Faith”
Opposing parties often cry “bad faith” when faced with a derivative action, pointing to the applicant’s personal grudges. This judgment serves as a reminder that proving bad faith is an uphill battle. The opposing party must show that the lawsuit is a mere sham—a collateral tool for personal leverage—rather than a genuine (even if self-interested) attempt to enforce corporate rights.
Closing
Corporate disputes are rarely just about the money; they are often deeply personal, driven by broken trust and simmering resentments. Dato’ Dr Lim Boon Ping v. Sun Pharmaceutical reminds us that while companies are legal persons separate from their shareholders, the humans pulling the strings are inevitably governed by human emotions.
For businesses operating in Malaysia, the takeaway is clear: statutory compliance cannot be treated as a formality, especially when the core relationships within the company begin to fracture. If you find yourself navigating the complex intersection of shareholder disputes, fiduciary duties, or matrimonial asset protection, seeking proper, tailored legal advice early is not just a option—it is a commercial necessity.
Important Notice
This article was prepared for educational purposes. If you are facing a similar situation, please consult with a licensed law practitioner before making a final decision. Please do not treat this article as a substitute for competent legal advice rendered by a licensed lawyer. Thank you for reading.